Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 21;23(4):95.
doi: 10.1208/s12249-022-02247-3.

A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines

Surojit Banerjee  1 , Debadri Banerjee  2 , Anupama Singh  2 , Vikas Anand Saharan  2
Affiliations
Review

A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines

Surojit Banerjee et al. AAPS PharmSciTech. .

Abstract

COVID-19 caused by coronavirus SARS-CoV-2 became a serious threat to humankind for the past couple of years. The development of vaccine and its immediate application might be the only to escape from the grasp of this demoniac pandemic. Approximately 343 clinical trials on COVID-19 vaccines are ongoing currently, and almost all countries are motivating ongoing researches at warp speed for the development of vaccines against COVID-19. This review explores the progress in the development of the vaccines, their current status of ongoing clinical research, mechanisms, and regulatory approvals. Many pharmaceutical companies are already in the endgame for manufacturing various vaccines of which some are already being marketed across the globe, while others are yet to get approval for marketing. The primary aim of this review is to compare regulatory accepted vaccines in terms of their composition, doses, regulatory status, and efficacy. The study is conducted by grouping into approved and unapproved vaccines for marketing. Different routes of administration of vaccines along with the efficacy of the routes are also presented in the review. A wide range of database and clinical trial data is reviewed for sorting out the information on different vaccines. Unfortunately, many mutations (alpha, beta, gamma, delta, kappa, omicron etc.) of SARS-CoV-2 have attacked people in very short time, which is the great challenge for investigational vaccines. Moreover, some vaccines like Pfizer's BNT162, Oxford's ChAdOx1, Moderna's mRNA-1273, and Bharat Biotech's Covaxin have got regulatory approval in some countries for its distribution which may prove to stand tall against the pandemic.

Keywords: clinical trials; covid-19; prevention; sars-cov-2; vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Mechanism of action of CD24Fc
Fig. 2
Fig. 2
Mechanism of action of aAPCs
Fig. 3
Fig. 3
Mechanism of action of ChAdOx1 (S-gp = S glycoprotein, Ab = antibodies)
Fig. 4
Fig. 4
Scientific challenges for the development, manufacturing, and distribution of COVID-19 vaccine
Fig. 5
Fig. 5
Clinical trials of approved vaccines at a glance
Fig. 6
Fig. 6
Clinical trials of unapproved vaccines at a glance
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Izda V, Jeffries MA, Sawalha AH. COVID-19: a review of therapeutic strategies and vaccine candidates. Clin Immunol. 2021;222:108634. doi: 10.1016/j.clim.2020.108634. - DOI - PMC - PubMed
    1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. doi: 10.1016/j.jaut.2020.102433. - DOI - PMC - PubMed
    1. Yüce M, Filiztekin E, Ozkaya KG. COVID-19 diagnosis — a review of current methods. Biosens Bioelectron. 2021;172:112752. doi: 10.1016/j.bios.2020.112752. - DOI - PMC - PubMed
    1. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382:929–936. doi: 10.1056/NEJMoa2001191. - DOI - PMC - PubMed
    1. Stasi C, Fallani S, Voller F, Silvestri C. Treatment for COVID-19: an overview. Eur J Pharmacol. 2020;889:173644. doi: 10.1016/j.ejphar.2020.173644. - DOI - PMC - PubMed